Shareholders of the biotech company JSC “RBT” (part of the “Artgen Biotech” ecosystem) have approved a decision to increase the authorized capital. The company plans to raise 60 million rubles in the first half of 2026 to implement an updated development strategy. This is reported by the company’s press service.
Placement Parameters
The additional share issue will be conducted via closed subscription. The Board of Directors of “RBT” has already approved the placement price at 130 rubles per share.
The funds raised will be used to finance the medium-term strategy adopted in November 2025. Its main goals are the development of key competencies in vaccine development and reducing dependence on third-party raw material suppliers.
“The company is raising funds to implement the updated medium-term strategy aimed at further developing the vaccine direction, launching new products, minimizing external risks and dependence on third-party suppliers. The company also plans to more actively use the licensing business model and product co-development.”
— Igor Krasilnikov, Director of JSC “RBT”
Human Vaccine Portfolio
The vaccine direction remains a priority for the company. The “RBT” portfolio currently includes three drugs at an advanced stage of development:
- “TetraFluBET” (for influenza);
- “Betuvax-CoV-2” (for coronavirus);
- Combined vaccine “Covid+Flu”.
The company intends to develop these projects by attracting partners under a licensing model. In parallel, “RBT” is focusing on creating vaccines that do not depend on external antigen supplies. In particular, the development of a vaccine against respiratory syncytial virus infection (RSV) began in 2025.
Veterinary Medicine and New Markets
To accelerate revenue generation, “RBT” is diversifying its business through new directions. The company is entering the high-margin segment of vaccines for animals, which is characterized by simpler regulatory procedures. Work on an oncovaccine for pets and an adjuvant for veterinary drugs already began in 2025.
MedTech and Production
Also, “RBT” plans to develop contract manufacturing of medical devices at the company’s pilot production site in the Perm region. This decision will significantly reduce time to market and provide the company with financial stability.
Among the company’s own new developments in this segment is an organ preservation solution.
